Cadila Healthcare Ltd Q1FY21 consolidated PAT at Rs. 454 crore

CADILA HEALTHCARE LTD. has reported financial results for the period ended June 30, 2020.

Financial Results (Q1 FY 2020-21) - QoQ Comparison

The company has reported total income of Rs.3662.4 crores during the period ended June 30, 2020 as compared to Rs.3796.4 crores during the period ended March 31, 2020.

The company has posted net profit / (loss) of Rs.454 crores for the period ended June 30, 2020 as against net profit / (loss) of Rs.391.9 crores for the period ended March 31, 2020.

The company has reported EPS of Rs.4.43 for the period ended June 30, 2020 as compared to Rs.3.83 for the period ended March 31, 2020.

Financials	Q1 FY2020-21	Q4 FY19-20	% Change
Total Income	₹ 3662.4 crs	₹ 3796.4 crs	-3.53%
Net Profit	₹ 454 crs	₹ 391.9 crs	15.85%
EPS	₹ 4.43	₹ 3.83	15.67%

Financial Results (Q1 FY 2020-21) - YoY Comparison

The company has reported total income of Rs.3662.4 crores during the period ended June 30, 2020 as compared to Rs.3518.9 crores during the period ended June 30, 2019.

The company has posted net profit / (loss) of Rs.454 crores for the period ended June 30, 2020 as against net profit / (loss) of Rs.303.6 crores for the period ended June 30, 2019.

The company has reported EPS of Rs.4.43 for the period ended June 30, 2020 as compared to Rs.2.97 for the period ended June 30, 2019.

Financials	Q1 FY2020-21	Q1 FY2019-20	% Change
Total Income	₹ 3662.4 crs	₹ 3518.9 crs	4.08%
Net Profit	₹ 454 crs	₹ 303.6 crs	49.54%
EPS	₹ 4.43	₹ 2.97	49.16%

Earnings before Interest, Depreciation and Tax (EBIDTA) for the quarter was Rs. 815 crores. EBIDTA margins for the quarter was 22.4%, an improvement of 360 basis points over the corresponding quarter of the previous financial year.

The company's India business which comprises human formulations, consumer wellness and animal health business posted sales of Rs.1486 crores during the quarter. After a quiet start to the quarter, businesses across India geography have shown gradual improvement on a month-on-month basis during the quarter.

The company's business in the US posted sales of Rs. 1623 crores, up by 19% on a y-o-y basis. The company received 12 ANDA approvals (incl. 4 tentative approvals), during the quarter. The company's rest of the world business grew by 8% during the quarter on a y-o-y basis and posted sales of Rs. 238 crores. Showing progress in its research efforts, the Company announced the USFDA approval to initiate clinical trials of Desidustat, its Investigational New Drug targeted at treating anemia in cancer patients, receiving chemotherapy.

Continuing with its efforts to look at new therapeutic options to manage and treat the COVID-19, Zydus received approvals from COFEPRIS of Mexico for clinical trials of Pegylated Interferon Alpha 2b in COVID 19 patients. At present, clinical trials in India and Mexico are underway with Pegylated Interferon alpha-2b. The Company also received an approval to conduct clinical trials with Desidustat, its Investigational New Drug, for the management of COVID 19 patients in Mexico from COFEPRIS. The company announced the commencement of the Adaptive Phase I/II clinical trials of ZYCoV-D, the preventive vaccine for COVID 19 in India.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.402.85 as compared to the previous close of Rs. 395.15. The total number of shares traded during the day was 461510 in over 8989 trades.

The stock hit an intraday high of Rs. 405.4 and intraday low of 390.6. The net turnover during the day was Rs. 183938841.

Source : Equity Bulls

Keywords